Inquirer architecture critic Inga Saffron reviews GlaxoSmithKline's new building at the Philadelphia Navy Yard
The Inquirer's architecture critic, Inga Saffron, toured and reviewed GlaxoSmithKline's new building at the Philadelphia Navy Yard.
Inquirer architecture critic Inga Saffron reviews GlaxoSmithKline's new building at the Philadelphia Navy Yard
David Sell
The Inquirer's architecture critic, Inga Saffron, toured and reviewed GlaxoSmithKline's new building at the Philadelphia Navy Yard.
A link to Inga's story in Friday's Inquirer is here.
The drugmaker's Center City employees have moved from their previous location at Franklin Plaza to the new facility.
Saturday is the official opening. Glaxo is based in London and since no one does pomp and circumstance like the British, there will surely be some of that.
Comments (0)
Popular Posts
Search this blog:
Blog Roll
- Adolor
- Almac
- AmerisourceBergen
- AstraZeneca
- Auxilium
- Bayer
- Celgene
- Cephalon
- Endo
- GlaxoSmithKline
- Johnson & Johnson
- Kensey Nash
- Lannett
- Merck
- Pfizer
- Roche
- Sanofi-aventis
- Shire
- Stryker
- Synthes
- Teva
- ViroPharma
- West
- Centers for Disease Control and Prevention
- Centers for Medicare and Medicaid
- Clinical Trials
- Food and Drug Administration
- Office of Inspector General, Health and Human Services
- OIG Most-wanted list of fugitives
- Securities and Exchange Commission/Edgar filings
- U.S. Attorney's Office/Eastern Pennsylvania, health-care fraud
- U.S. Department of Health and Human Services
- BIO
- Jersey Association of Medical Equipment Services
- Pennsylvania Association of Medical Suppliers
- Pharmaceutical Research and Manufacturers of America
- Science Center
- American Health Lawyers Association
- Drug and Device Law
- Orange Book blog
- Taxpayers Against Fraud
- Bio Century
- Bio Space
- Cafe Pharma
- Financial Times
- In The Pipeline
- Monday Morning
- New York Times/Prescriptions
- Pharma Live
- Pharma Marketing
- Pharmalot
- The Placebo Effect
- Wall Street Journal/Health blog



